Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)
China · Delayed Price · Currency is CNY 281.00
-1.83 (-0.65%)
At close: Feb 6, 2026
SHA:688506 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,224 | 5,821 | 560.42 | 701.83 | 794.95 | 1,011 |
Other Revenue | 1.67 | 1.67 | 1.46 | 1.45 | 1.78 | 1.66 |
| 2,226 | 5,823 | 561.87 | 703.28 | 796.73 | 1,013 | |
Revenue Growth (YoY) | -61.93% | 936.31% | -20.11% | -11.73% | -21.33% | -16.07% |
Cost of Revenue | 251.38 | 283.74 | 242.26 | 237.7 | 203.39 | 202.02 |
Gross Profit | 1,975 | 5,539 | 319.61 | 465.58 | 593.34 | 810.69 |
Selling, General & Admin | 509.03 | 405.04 | 367.89 | 403.01 | 467.46 | 636.86 |
Research & Development | 2,283 | 1,443 | 746.23 | 375.02 | 278.6 | 195.7 |
Other Operating Expenses | 15.86 | 4.24 | -2.27 | 9.79 | 9.17 | 3 |
Operating Expenses | 2,809 | 1,853 | 1,105 | 795.41 | 752.86 | 833.55 |
Operating Income | -833.88 | 3,686 | -785.6 | -329.83 | -159.52 | -22.85 |
Interest Expense | -73.62 | -42.52 | -24.68 | -22.48 | -8.69 | -7.57 |
Interest & Investment Income | 245.81 | 225.32 | 5.71 | 0.77 | 3.61 | 4.75 |
Currency Exchange Gain (Loss) | 63.88 | 63.88 | -1.11 | -0.05 | -0.14 | - |
Other Non Operating Income (Expenses) | 7.4 | -3.38 | -0.84 | -0.56 | -0.35 | 0.02 |
EBT Excluding Unusual Items | -590.4 | 3,930 | -806.51 | -352.16 | -165.09 | -25.66 |
Gain (Loss) on Sale of Investments | 6.33 | 11.44 | - | - | - | 0.34 |
Gain (Loss) on Sale of Assets | -0.22 | -0.22 | -0.14 | -0.48 | -0.45 | - |
Asset Writedown | -10.14 | - | - | - | - | -0.17 |
Other Unusual Items | 37.3 | 37.3 | 37.64 | 63.57 | 61.1 | 71.11 |
Pretax Income | -557.13 | 3,978 | -769.01 | -289.07 | -104.44 | 45.62 |
Income Tax Expense | 295.25 | 270.65 | 11.49 | -6.69 | -4.45 | 7.7 |
Earnings From Continuing Operations | -852.38 | 3,708 | -780.5 | -282.38 | -99.99 | 37.92 |
Minority Interest in Earnings | - | - | - | - | - | -0.02 |
Net Income | -852.38 | 3,708 | -780.5 | -282.38 | -99.99 | 37.9 |
Net Income to Common | -852.38 | 3,708 | -780.5 | -282.38 | -99.99 | 37.9 |
Net Income Growth | - | - | - | - | - | 390.26% |
Shares Outstanding (Basic) | 402 | 401 | 400 | 362 | 357 | 345 |
Shares Outstanding (Diluted) | 402 | 401 | 400 | 362 | 357 | 345 |
Shares Change (YoY) | 0.63% | 0.14% | 10.56% | 1.38% | 3.64% | -10.86% |
EPS (Basic) | -2.12 | 9.25 | -1.95 | -0.78 | -0.28 | 0.11 |
EPS (Diluted) | -2.12 | 9.25 | -1.95 | -0.78 | -0.28 | 0.11 |
EPS Growth | - | - | - | - | - | 450.00% |
Free Cash Flow | -2,548 | 3,975 | -697.29 | -293.21 | -179.63 | 63.09 |
Free Cash Flow Per Share | -6.34 | 9.92 | -1.74 | -0.81 | -0.50 | 0.18 |
Gross Margin | 88.71% | 95.13% | 56.88% | 66.20% | 74.47% | 80.05% |
Operating Margin | -37.46% | 63.31% | -139.82% | -46.90% | -20.02% | -2.26% |
Profit Margin | -38.29% | 63.67% | -138.91% | -40.15% | -12.55% | 3.74% |
Free Cash Flow Margin | -114.45% | 68.26% | -124.10% | -41.69% | -22.55% | 6.23% |
EBITDA | -758.81 | 3,754 | -727.25 | -272.27 | -109.37 | 26.45 |
EBITDA Margin | -34.09% | 64.48% | -129.43% | -38.71% | -13.73% | 2.61% |
D&A For EBITDA | 75.06 | 67.9 | 58.34 | 57.56 | 50.16 | 49.31 |
EBIT | -833.88 | 3,686 | -785.6 | -329.83 | -159.52 | -22.85 |
EBIT Margin | -37.46% | 63.31% | -139.82% | -46.90% | -20.02% | -2.26% |
Effective Tax Rate | - | 6.80% | - | - | - | 16.87% |
Revenue as Reported | 2,226 | 5,823 | 561.87 | 703.28 | 796.73 | 1,013 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.